



**SZABO
SCANDIC**

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com



www.szabo-scandic.com

linkedin.com/company/szaboscandic



UT501a : Endometrioid carcinoma tissue array with normal tissue as control, including TNM, clinical stage and pathology grade, 50 cases/ 50 cores

| | |
|--------------------|--|
| Microarray Panel | Endometrioid carcinoma tissue microarray with normal tissue, containing 41 cases of endometrioid adenocarcinoma, plus 2 each of serous adenocarcinoma and clear cell adenocarcinoma, 5 cases of normal tissue, single core per case |
| Cores | 50 |
| Cases | 50 |
| Row number | 5 |
| Column number | 10 |
| Core Diameter (mm) | 1.5 |
| Thickness (μm) | 5 |
| Tissue Array Type | FFPE |
| Species | Human |
| Applications | Routine histology procedures including Immunohistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found at our support page. |
| Notes | <p>1. TMA slides were sectioned and stored at 4°C and may not be fresh cut, but still suitable for IHC. Please request fresh cut if experiment involves phospho-specific antibodies, RNA studies, FISH or ISH, etc. A minimum of 3 slides per TMA must be purchased to cover the cost of trimming for fresh sectioning. 2. Most TMA slides were not coated with an extra layer of paraffin (tissue cores can be easily seen on the glass). To prevent tissue detachment during antigen retrieval, unbaked slides must be baked for at least 30 to 120 minutes at 60°C. before putting into xylene for de-paraffinization. Baked slides were sent out baked for 2 hours.</p> <p>In the following specsheets, “*” means invalid core; “-” means no applicable or negative in IHC markers.</p> |



Legend: Ute - Uterus

● - Malignant tumor, ○ - Malignant tumor (stage I), □ - Malignant tumor (stage IA), △ - Malignant tumor (stage IB), ▲ - Malignant tumor (stage IC), ■ - Malignant tumor (stage IIA),
 ▨ - Malignant tumor (stage IIB), ▤ - Malignant tumor (stage III), ▥ - Malignant tumor (stage IIIA), ▦ - Malignant tumor (stage IIIC), ▶ - Normal tissue
 , tissue IDs are available in exported Excel files.

| Pos. | No. | Age | Sex | Organ/Anatomic Site | Pathology diagnosis | TNM | Grade | Stage | Type | Image |
|------|-----|-----|-----|---------------------|--|---------|-------|-------|-----------|-------|
| A1 | 1 | 40 | F | Uterus | Endometrioid adenocarcinoma | T1bN0M0 | 1 | IB | malignant | |
| A2 | 2 | 62 | F | Uterus | Endometrioid adenocarcinoma | T1N0M0 | 1 | I | malignant | |
| A3 | 3 | 63 | F | Uterus | Endometrioid adenocarcinoma | T1bN0M0 | 1 | IB | malignant | |
| A4 | 4 | 58 | F | Uterus | Endometrioid adenocarcinoma | T1cN0M0 | 1 | IC | malignant | |
| A5 | 5 | 40 | F | Uterus | Endometrioid adenocarcinoma (sparse) | T1bN0M0 | 1 | IB | malignant | |
| A6 | 6 | 51 | F | Uterus | Endometrioid adenocarcinoma | T1bN0M0 | 1 | IB | malignant | |
| A7 | 7 | 57 | F | Uterus | Endometrioid adenocarcinoma | T1bN0M0 | 1 | IB | malignant | |
| A8 | 8 | 52 | F | Uterus | Endometrioid adenocarcinoma | T1cN0M0 | 1 | IC | malignant | |
| A9 | 9 | 45 | F | Uterus | Endometrioid adenocarcinoma | T1aN0M0 | 1 | IA | malignant | |
| A10 | 10 | 51 | F | Uterus | Endometrioid adenocarcinoma | T1bN0M0 | 1 | IB | malignant | |
| B1 | 11 | 68 | F | Uterus | Endometrioid adenocarcinoma | T1cN0M0 | 1 | IC | malignant | |
| B2 | 12 | 62 | F | Uterus | Endometrioid adenocarcinoma | T1bN0M0 | 1 | IB | malignant | |
| B3 | 13 | 59 | F | Uterus | Endometrioid adenocarcinoma | T1bN0M0 | 1 | IB | malignant | |
| B4 | 14 | 51 | F | Uterus | Endometrioid adenocarcinoma | T1bN0M0 | 1 | IB | malignant | |
| B5 | 15 | 62 | F | Uterus | Endometrioid adenocarcinoma | T1cN1M0 | 1 | IIIC | malignant | |
| B6 | 16 | 56 | F | Uterus | Endometrioid adenocarcinoma | T1bN0M0 | 1 | IB | malignant | |
| B7 | 17 | 62 | F | Uterus | Endometrioid adenocarcinoma | T1bN0M0 | 1 | IB | malignant | |
| B8 | 18 | 50 | F | Uterus | Endometrioid adenocarcinoma | T1bN0M0 | 1 | IB | malignant | |
| B9 | 19 | 60 | F | Uterus | Endometrioid adenocarcinoma | T1cN0M0 | 1 | IC | malignant | |
| B10 | 20 | 51 | F | Uterus | Endometrioid adenocarcinoma | T1bN0M0 | 1--2 | IB | malignant | |
| C1 | 21 | 60 | F | Uterus | Endometrioid adenocarcinoma | T1bN0M0 | 1--2 | IB | malignant | |
| C2 | 22 | 55 | F | Uterus | Endometrioid adenocarcinoma | T1cN0M0 | 1--2 | IC | malignant | |
| C3 | 23 | 61 | F | Uterus | Endometrioid adenocarcinoma | T1cN0M0 | 1 | IC | malignant | |
| C4 | 24 | 68 | F | Uterus | Endometrioid adenocarcinoma | T1cN0M0 | 1 | IC | malignant | |
| C5 | 25 | 60 | F | Uterus | Endometrioid adenocarcinoma | T1bN0M0 | 1 | IB | malignant | |
| C6 | 26 | 50 | F | Uterus | Endometrioid adenocarcinoma (smooth muscle tissue) | T1bN0M0 | - | IB | malignant | |
| C7 | 27 | 52 | F | Uterus | Endometrioid adenocarcinoma | T1bN0M0 | 2 | IB | malignant | |

| | | | | | | | | | |
|-----|----|----|---|---------------|---|---------|-----|------|-----------|
| C8 | 28 | 67 | F | Uterus | Endometrioid adenocarcinoma | T1cN0M0 | 1 | IC | malignant |
| C9 | 29 | 72 | F | Uterus | Endometrioid adenocarcinoma | T1bN0M0 | 1 | IB | malignant |
| C10 | 30 | 55 | F | Uterus | Endometrioid adenocarcinoma | T1bN0M0 | 1 | IB | malignant |
| D1 | 31 | 57 | F | Uterus | Endometrioid adenocarcinoma | T1bN0M0 | 2 | IB | malignant |
| D2 | 32 | 58 | F | Uterus | Endometrioid adenocarcinoma | T1bN0M0 | 3 | IB | malignant |
| D3 | 33 | 52 | F | Uterus | Endometrioid adenocarcinoma (smooth muscle tissue) | T1bN0M0 | - | IB | malignant |
| D4 | 34 | 53 | F | Uterus | Endometrioid adenocarcinoma | T1cN0M0 | 3 | IC | malignant |
| D5 | 35 | 53 | F | Uterus | Endometrioid adenocarcinoma | T1cN0M0 | 3 | IC | malignant |
| D6 | 36 | 47 | F | Uterus | Endometrioid adenocarcinoma | T1cN0M0 | 3 | IC | malignant |
| D7 | 37 | 62 | F | Uterus | Endometrioid adenocarcinoma | T1cN0M0 | 3 | IC | malignant |
| D8 | 38 | 65 | F | Uterus | Endometrioid adenocarcinoma with squamous metaplasia | T1bN0M0 | 3 | IB | malignant |
| D9 | 39 | 54 | F | Uterus | Endometrioid adenocarcinoma | T1cN0M0 | 3 | IC | malignant |
| D10 | 40 | 56 | F | Uterus | Endometrioid adenocarcinoma (chronic inflammation of smooth muscle) | T2aN0M0 | - | IIA | malignant |
| E1 | 41 | 48 | F | Uterus | Endometrioid adenocarcinoma | T3N0M0 | 3 | III | malignant |
| E2 | 42 | 49 | M | Uterus | Serous adenocarcinoma | T1bN0M0 | 2-3 | IB | malignant |
| E3 | 43 | 60 | F | Uterus | Serous adenocarcinoma | T3aN0M0 | 1 | IIIA | malignant |
| E4 | 44 | 72 | F | Uterus | Clear cell adenocarcinoma | T1cN0M0 | 2 | IC | malignant |
| E5 | 45 | 50 | F | Uterus | Clear cell adenocarcinoma | T2bN0M0 | 2 | IIB | malignant |
| E6 | 46 | 21 | F | Uterus | Normal endometrium tissue | - | - | - | normal |
| E7 | 47 | 41 | F | Uterus | Normal endometrium tissue | - | - | - | normal |
| E8 | 48 | 18 | F | Uterus | Normal endometrium tissue | - | - | - | normal |
| E9 | 49 | 21 | F | Uterus | Normal endometrium tissue | - | - | - | normal |
| E10 | 50 | 21 | F | Uterus | Normal endometrium tissue (smooth muscle and blood vessel) | - | - | - | normal |
| - | 0 | 42 | M | Adrenal gland | Pheochromocytoma (tissue marker) | - | - | - | Malignant |

AMSBIO | www.amsbio.com | info@amsbio.com

AMSBIO LLC
USA & Canada 
1035 Cambridge Street,
Cambridge, MA 02141
T: +1 (617) 945-5033 or
T: +1 (800) 987-0985
F: +1 (617) 945-8218

AMSBIO Europe BV
EU 
Berenkoog 41,
1822 BH Alkmaar,
Netherlands
T: +31 (0) 72 8080244
F: +31 (0) 72 8080142

AMSBIO Biotechnology (Europe) Ltd
UK & Rest of the World 
184 Park Drive, Milton Park
Abingdon OX14 4SE
T: +44 (0) 1235 828 200
F: +44 (0) 1235 820 482

AMSBIO Biotechnology (Europe) Ltd
Switzerland 
Via Lisano 3,
(CP.683)
CH-6900 Massagno
T: +41 (0) 91 604 55 22
F: +41 (0) 91 605 17 85

AMSBIO Europe BV
Deutschland 
T: +49 (0) 69 779099
F: +49 (0) 69 13376880